Neurological complications of psychiatric drugs: clinical features and management
Open accessThe DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
This paper reviews the main neurological complications of psychiatric drugs, in particular antipsychotics and antidepressants. Extrapyramidal syndromes include acute dystonia, parkinsonism, akathisia, tardive dyskinesia and tardive dystonia. Extrapyramidal symptoms (EPS) are less frequent with atypical than with conventional antipsychotics but remain common in clinical practice partly due to lack of screening by health professionals. Neuroleptic malignant syndrome (NMS) consists of severe muscle rigidity, pyrexia, change in conscious level and autonomic disturbance but partial forms also occur. NMS is particularly associated with the initiation and rapid increase in dose of high-potency antipsychotics but it has been reported with all the atypical antipsychotics and rarely with other drugs including antidepressants. Serotonin toxicity comprises altered mental state (agitation, excitement, confusion), neuromuscular hyperactivity (tremor, clonus, myoclonus, hyper-reflexia) and autonomic hyperactivity and occurs on a spectrum. Severe cases, termed serotonin syndrome, usually follow the co-prescription of drugs that increase serotonergic transmission by different pathways, for example a monoamine oxidase inhibitor (MAOI) and a selective serotonin reuptake inhibitor (SSRI). Most antipsychotics and antidepressants lower the seizure threshold and can cause seizures; the risk is greater with clozapine than with other atypical antipsychotics and greater with tricyclic antidepressants (TCAs) than with SSRIs. In randomised controlled trials in elderly patients with dementia atypical antipsychotics are associated with a higher risk of stroke and death than placebo. Cohort studies suggest that conventional drugs carry at least the same risk. Cessation of treatment with antipsychotics and antidepressants can lead to a wide range of discontinuation symptoms which include movement disorders and other neurological symptoms. Clinicians need to be familiar with strategies to reduce the risk of these adverse events and to manage them when they arise. Their occurrence needs to be balanced against the benefits of psychiatric drugs in terms of efficacy and improved quality of life in a range of disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., Keefe, R. S. E., Davis, S. M., Davis, C. E., Lebowitz, B. D., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051688 · Cited by 5,892
Schneider, L. S., Dagerman, K. S., & Insel, P. (2005) · JAMA · doi:10.1001/jama.294.15.1934 · Cited by 1,671 · cited 2×
“In summary several meta-analyses (CSM, 2004; Schneider et al., 2005, 2006a) show that atypical antipsychotics are associated with a higher risk of stroke or death than placebo in elderly patients with dementia.”
BackgroundInfluentialEffectiveness of Atypical Antipsychotic Drugs in Patients with Alzheimer's Disease
Schneider, L. S., Tariot, P. N., Dagerman, K. S., Davis, S. M., Hsiao, J. K., Ismail, M. S., Lebowitz, B. D., Lyketsos, C. G., Ryan, J. M., Stroup, T. S., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061240 · Cited by 1,206
Egger, M., Jüni, P., Bartlett, C., Holenstein, F., & Sterne, J. (2003) · Health Technology Assessment · doi:10.3310/hta7010 · Cited by 1,181
Schneider, L. S., Dagerman, K., & Insel, P. S. (2006) · The American Journal of Geriatric Psychiatry · doi:10.1097/01.jgp.0000200589.01396.6d · Cited by 903
Calabrese, J. R., Keck, P. E., Macfadden, W., Minkwitz, M., Ketter, T. A., Weisler, R. H., Cutler, A. J., McCoy, R., Wilson, E., Mullen, J., et al. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.7.1351 · Cited by 883 · cited 1×
“There is increasing evidence that specific atypical antipsychotics may have benefit in other phases of bipolar illness (Calabrese et al., 2005; Tohen et al., 2005).”
BackgroundPharmacotherapy for post traumatic stress disorder (PTSD)
Stein, D. J., Ipser, J. C., Seedat, S., Sager, C., & Amos, T. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002795.pub2 · Cited by 519 · cited 2×
“Randomised controlled trials indicate the efficacy of antidepress- Copyright # 2007 John Wiley & Sons, Ltd. ants in the treatment of depressive illness (National Institute for Clinical Excellence, 2004) and several other affective disorders (e.g. Kapczinski et al., 2003; Stein et al., 2006).”
BackgroundGill, S. S., Rochon, P. A., Herrmann, N., Lee, P. E., Sykora, K., Gunraj, N., Normand, S.-L. T., Gurwitz, J. H., Marras, C., Wodchis, W. P., et al. (2005) · BMJ · doi:10.1136/bmj.38330.470486.8f · Cited by 402
Antidepressant Discontinuation Syndromes: Clinical Relevance, Prevention and Management
Haddad, P. M. (2001) · Drug Safety · doi:10.2165/00002018-200124030-00003 · Cited by 214 · cited 8×
“Most antipsychotics and antidepressants lower the seizure threshold and can cause seizures; the risk is greater with clozapine than with other atypical antipsychotics and greater with tricyclic antidepressants (TCAs) than with SSRIs.”
BackgroundInfluentialSelf-citationPerlis, R. H., Welge, J. A., Vornik, L. A., Hirschfeld, R. M. A., & Keck, P. E. (2006) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v67n0401 · Cited by 196 · cited 2×
“, 2003b) and the treatment of mania (Perlis et al., 2006).”
Background
Cited by
Correll, C. U., Detraux, J., De Lepeleire, J., & De Hert, M. (2015) · World Psychiatry · doi:10.1002/wps.20204 · Cited by 820
“Antidepressants can also lower the seizure risk threshold (91,276), with intermediate epileptogenic potential for tricyclic antidepressants and lower epileptogenic potential for bupropion (277), which is still contraindicated in people with seizure disorders (Table 2).”
BackgroundCarvalho, A. F., Sharma, M. S., Brunoni, A. R., Vieta, E., & Fava, G. A. (2016) · Psychotherapy and Psychosomatics · doi:10.1159/000447034 · Cited by 650
Schizophrenia: overview and treatment options.
(2014) · PubMed Central · Cited by 533
Baldessarini, R. J. (2013) · doi:10.1007/978-1-4614-3710-9 · Cited by 365
Addressing the Side Effects of Contemporary Antidepressant Drugs: A Comprehensive Review
Wang, S.-M., Han, C., Bahk, W.-M., Lee, S.-J., Patkar, A. A., Masand, P. S., & Pae, C.-U. (2018) · Chonnam Medical Journal · doi:10.4068/cmj.2018.54.2.101 · Cited by 299
“Classical studies showed that epileptogenic potential is higher for TCAs than for bupropion, so TCAs are still contraindicated for individuals with seizure disorders.(53) However, recent studies concerning seizure were contradictory.”
BackgroundPreti, A., & Cella, M. (2010) · Schizophrenia Research · doi:10.1016/j.schres.2010.07.026 · Cited by 167
Treatment of cocaine cardiovascular toxicity: a systematic review
Richards, J. R., Garber, D., Laurin, E. G., Albertson, T. E., Derlet, R. W., Amsterdam, E. A., Olson, K. R., Ramoska, E. A., & Lange, R. A. (2016) · Clinical Toxicology · doi:10.3109/15563650.2016.1142090 · Cited by 116
Richards, J. R., Albertson, T. E., Derlet, R. W., Lange, R. A., Olson, K. R., & Horowitz, B. Z. (2015) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2015.01.040 · Cited by 107
Treatment-emergent adverse events associated with atypical antipsychotics
Cha, D. S., & McIntyre, R. S. (2012) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2012.656590 · Cited by 68
Köster, M., Grohmann, R., Engel, R. R., Nitsche, M. A., Rüther, E., & Degner, D. (2013) · Psychopharmacology · doi:10.1007/s00213-013-3281-8 · Cited by 18
Medical Complications of Psychiatric Treatment
Lahijani, S. C., & Harris, K. A. (2017) · Critical Care Clinics · doi:10.1016/j.ccc.2017.03.008 · Cited by 8
Metadata
- Authors
- Haddad, P. M., & Dursun, S. M.
- Venue
- Human Psychopharmacology: Clinical and Experimental
- Publisher
- Wiley
- Published
- 2007
- Volume
- 23
- Issue
- S1
- Pages
- S15-S26
- ISSN
- 0885-6222 (ISSN-L)
- 1099-1077
- OpenAlex
- W2044995057
- Cited by
- 223
- References
- 17
- FWCI
- 10.92
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.